BioSpace News Archive

Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has tentatively approved the Company’s Abbreviated New Drug Application for Vasopressin injection, USP 20 Units/mL, 1mL Single Dose Vial.

Collaborative Health Systems (CHS) announced today that its collective support and services have helped Medicare healthcare providers achieve $91 million in total savings through the Next Generation Accountable Care Organization.

Paragon 28, Inc. today announced that the U.S. Food and Drug Administration (FDA) has given 501(k) marketing clearance to its R3ACT™ Stabilization System.

Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 33.5 million of its shares.

Bio-Thera Solutions, Ltd. today announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics and safety of BAT6005, a monoclonal antibody targeting TIGIT in cancer patient volunteers.

Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock.

Organicell Regenerative Medicine, Inc. is pleased to provide its stockholders and the investment community with the following updates regarding its approved Investigational New Drug Applications and other clinical trial related activities surrounding Zofin.

Amedisys, Inc. today announced that Paul B. Kusserow, Chairman and Chief Executive Officer, Chris Gerard, President and Chief Operating Officer and Scott Ginn, Executive Vice President and Chief Financial Officer will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, at 3:45 p.m. EST.

P3 Health Partners Inc. today announced that its Chief Executive Officer, Dr. Sherif Abdou, and members of the P3 management team will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 5:15 p.m. (ET) / 2:15 p.m. (PT).

Diversified Healthcare Trust (Nasdaq: DHC) today announced that it has entered into an agreement with a global institutional investor to acquire an equity interest in DHC’s existing joint venture that owns the two building life science complex located at 11 Fan Pier and 50 Northern Avenue in Boston, MA.